The MarketWatch News Department was not involved in the creation of this content. Faster Clinical Translation and Commercialization of Therapies Derived From iPSC Technology GERMANTOWN, MARYLAND / ...
SEATTLE--(BUSINESS WIRE)--Pluristyx, a leading provider of Good Manufacturing Practices (GMP), cutting-edge, induced pluripotent stem cell (iPSC) technologies, today announced the immediate ...
SEATTLE--(BUSINESS WIRE)--Pluristyx, a leading provider of innovative, unmodified, and gene-edited induced pluripotent stem cell (iPSC) lines, submitted a Type II Drug Master File (DMF) to the U.S.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback